Pharmacomechanical thrombolysis for acute deep vein thrombosis tied to kidney injury
Moderna says Covid vaccine durable for at least six months
5 August 2021A COVID-19 biomarker: Low blood levels of sphingosine predict symptomatic infections
5 August 2021Pharmacomechanical thrombolysis for acute deep vein thrombosis tied to kidney injury
(HealthDay)—Use of pharmacomechanical thrombolysis (PMT) for treatment of acute deep vein thrombosis (DVT) is associated with a risk for acute kidney injury (AKI) that can progress to chronic renal failure in some patients, according to a study published in the July issue of the Journal of Vascular Surgery: Venous and Lymphatic Disorders.
